12-07-2012: Horizon Discovery Ltd announced it has signed a collaboration agreement with Bayer Pharma AG (Bayer) to develop preclinical cell line models that will support Bayer’s oncology research and development programs, using Horizon’s precision genome editing technology, GENESIS™. The aim of the collaboration is to deliver high quality cell lines that more accurately model the disease-relevant mutations found in human tumors.
Using GENESIS, Horizon is able to alter any endogenous gene sequence of human or mammalian cell lines quickly, reliably and without unwanted and confounding genotypes and/or phenotypes. With the ability to rapidly introduce one or more significant gain-of-function disease-relevant mutations (common in many forms of cancer), as well as loss-of-function alterations, into any endogenous gene loci of human cells, GENESIS can more accurately reflect patient genotypes in human cancer cell lines derived from human tumors. Under the terms of the agreement, Horizon will apply GENESIS to develop human isogenic cell lines for use in Bayer’s oncology research and development programs.
Financial terms of the agreement are not disclosed.
Horizon Discovery Ltd announced it has signed a research service collaboration agreement with Boehringer Ingelheim. Horizon will support Boehringer Ingelheim’s oncology programs by using its Discovery Toolbox for research projects and profiling of compounds at the hit-to-lead, lead optimiza ... more
Horizon Discovery Ltd announced it has signed an agreement with Domainex to support Domainex’s TBK1/ IKKe oncology research and development program, which is conducted in collaboration with The Institute of Cancer Research, London. Under the terms of the agreement, Horizon will profile a n ... more
Horizon Discovery Limited has announced the appointment of Mr. Richard Vellacott as Chief Financial Officer.
Richard has over 15 years’ experience in working with life science companies, from start-ups to global pharmaceuticals, and is a chartered accountant with a first class degree in Bio ... more
Bayer HealthCare has submitted the oral investigational drug Riociguat to treat patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) for regulatory approval in the United States and in the European Union.
“These regulatory ... more
QIAGEN and Bayer HealthCare announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. Companion diagnostics are tests that unlock molecular info ... more
The Lead Discovery Center GmbH (LDC) announced that a kinase inhibitor program licensed to Bayer Pharma AG, Germany (Bayer) last year, has reached an important transition milestone. Bayer has successfully advanced this kinase inhibitor program into pre-clinical development with the goal of ... more
Bayer Pharmaceutical Manufacturing Services is committed to providing our contract manufacturing partners with the unsurpassed quality and compliance associated with Bayer during the past 100 years.
We are driven to achieve our partners' pharmaceutical manufacturing goals by offering a div ... more